Meeting
2021 ASCO Annual Meeting
Outcome and immune landscape of HER2-positive invasive lobular carcinoma in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) trial.
Authors
Saranya Chumsri
Mayo Clinic, Jacksonville, FL
Saranya Chumsri , Zhuo Li , Tracy Shachner , Pooja Advani , Kostandinos Sideras , Alvaro Moreno-Aspitia , Gerardo Colon-Otero , Keith L. Knutson , Aziza Nassar , Edith A. Perez , E Aubrey Thompson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00005970
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 535)
DOI
10.1200/JCO.2021.39.15_suppl.535
Abstract #
535
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.
First Author: Sonya Chew
Poster
2021 ASCO Annual Meeting
Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).
First Author: Sun Young Rha
Poster
2020 ASCO Virtual Scientific Program
Value of clinical treatment score post-5 years (CTS5) for late relapse risk assessment in patients with early-stage HER2+ breast cancer (BC) in the north central cancer treatment group (NCCTG) N9831 (Alliance) trial.
First Author: Tanmayi Pai
Poster
2020 Gastrointestinal Cancers Symposium
Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts).
First Author: Stacey Stein